Elizabeth Needham Waddell

Elizabeth Needham Waddell

Auto-generated profile, based on publicly available information

Elizabeth Needham Waddell

Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2006 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
EWElizabeth Needham Waddell
Elizabeth Needham Waddell
PMPeter A. Messeri
Peter A. Messeri

1 November 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
DHDaniel B. Hoover
Daniel B. Hoover
PKPhilip Todd Korthuis
Philip Todd Korthuis
EWElizabeth Needham Waddell
Elizabeth Needham Waddell
CFCanyon Foot
Canyon Foot
CCCaitlin Conway
Caitlin Conway
RCRyan Cook
Ryan Cook
The US spends $80.7 billion annually on correctional agencies, including jails and prisons, excluding the associated cost burdens on incarcerated persons, their families, and their communities.1,2 The US drug prohibition policies have failed to discourage drug use or to curtail an increasingly dangerous contaminated drug supply and have contributed to mass incarceration that disproportionately harms Black or African American and Latinx populations.3,4 In the Survey of Prison Inmates, 2016,5 47% of adults in custody met criteria for a substance use disorder (SUD) diagnosis. According to the 2019 census of jails, 15% of individuals in jail screened positive for opioid use disorder, but only 24% of jails allowed continuation of medications for opioid use disorder (MOUD) while in custody.6

10 July 2020 in Health & Justice
Verified
Journal Article
Open access
PDF file
EWElizabeth Needham Waddell
Elizabeth Needham Waddell
RBRobin Baker
Robin Baker
DHDaniel M. Hartung
Daniel M. Hartung
CHChristi J. Hildebran
Christi J. Hildebran
TNThuan Nguyen
Thuan Nguyen
KWKatharina Wiest
Katharina Wiest
Background: Drug overdose is the leading cause of death after release from prison, and this risk is significantly higher among women compared to men. Within the first 2 weeks after release, the risk of death from drug overdose is 12.7 times higher than the general population, with risk of death further elevated among females. Although female inmates have higher rates of opioid use disorder and post-release overdose fatality, justice-involved women are under-represented in studies of medications for opioid use disorder. The Reducing Overdose After Release from Incarceration (ROAR) pilot intervention and evaluation (recruitment June 2019 through December 2020) aims to reduce opioid overdose among women released to the community following incarceration in state prison. The evaluation further assesses induction, acceptance and effectiveness of extended release naltrexone in a female post-prison population. Methods/design: In the week prior to their release, female adults in custody with moderate to severe opioid use disorder start treatment with extended release naltrexone, an injectable opioid antagonist that blocks the effects of opioids for up to 1 month. All ROAR participants receive training to use naloxone rescue kits and are provided nasal naloxone at release. Ongoing support from a certified recovery mentor to facilitate sustained engagement with treatment for substance use disorders begins in the month prior to release from prison and continues for 6 months in community. We evaluate the association between ROAR participation and the primary outcome of opioid overdose. Using administrative data provided by the Oregon Department of Corrections and the Oregon Health Authority, we compare the odds of overdose among ROAR participants versus a comparison group of females released from prison during the study period. Evaluation activities in community includes survey and qualitative interviews for 6 months post release, as well as a review of clinic records to assess retention on medication among the pilot cohort (N = 100). Discussion: ROAR is a collaboration between Oregon’s public health, criminal justice, and medical communities. The ROAR intervention and evaluation provide critical information on improving interventions to prevent opioid overdose and improve retention on treatment in community in an overlooked, high-risk population: incarcerated women re-entering the community. Trial registration: Clinical Trials.gov TRN: NCT03902821.

11 April 2010 in Journal of Urban Health
Verified
Journal Article
Closed access
PDF file
EWElizabeth Needham Waddell
Elizabeth Needham Waddell
MOMark G. Orr
Mark G. Orr
JSJudith Sackoff
Judith Sackoff
JSJohn S. Santelli
John S. Santelli

21 November 2019 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
KHKim A. Hoffman
Kim A. Hoffman
RBRobin Baker
Robin Baker
LKLynn E. Kunkel
Lynn E. Kunkel
EWElizabeth Needham Waddell
Elizabeth Needham Waddell
PLPaula J. Lum
Paula J. Lum
PKPhilip Todd Korthuis
Philip Todd Korthuis
Background: The CTN-0067 CHOICES trial tests implementation of extended-release naltrexone (XR-NTX) versus treatment-as-usual (TAU) for opioid use disorders (OUD) in HIV clinics to improve HIV viral suppression. The study team investigated recruitment strategies to elucidate the barriers and facilitators to recruitment and enrollment in the study. Main text: Methods: Semi-structured, in-depth, digitally recorded interviews were completed with study recruitment-related staff and medical providers (n = 26) from six participating HIV clinics in the fall of 2018. Interviews probed 1) factors that might prevent prospective participants from engaging in study recruitment and enrollment procedures and 2) strategies used by study staff that encourage eligible patient participation. Interviews were transcribed and thematically analyzed using a content analysis approach. Results: All respondents reported that barriers to recruitment and enrollment included challenging patient social and structural factors (e.g., homelessness or living environments with high substance use, criminal justice involvement), difficulty locating patients with unsuppressed HIV viral load and OUD within the HIV clinic, time-consuming study enrollment processes, and stigma around HIV and OUD which inhibited treatment seeking. Some respondents observed that distrust of research and researchers impeded recruitment activities in the community. A specific medication-related barrier was patient fear of opioid abstinence required prior to XR-NTX induction. Facilitators of recruitment included use of trusted peer outreach/recruitment workers in the community, hospitalizations that offered windows of opportunities for screening and XR-NTX induction, providing participant transportation, and partnerships with harm reduction organizations for referrals. Conclusions: Though study personnel encountered barriers to recruitment in the CHOICES study, persons with untreated HIV and OUD can be enrolled in multisite clinical trials by using enhanced recruitment strategies that extend outside of the HIV clinic. Employing peer outreach workers and collaborating with syringe service programs may be especially helpful in facilitating recruitment and merit inclusion in similar study protocols.

1 June 2010
Verified
Journal Article
Closed access
SRSwapnil N. Rajpathak
Swapnil N. Rajpathak
LGLeena S. Gupta
Leena S. Gupta
EWElizabeth Needham Waddell
Elizabeth Needham Waddell
UUUshma D. Upadhyay
Ushma D. Upadhyay
RWRachel P. Wildman
Rachel P. Wildman
JWJudith Wylie-Rosett
Judith Wylie-Rosett